We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Astellas Pharma Inc. (ALPMY - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Astellas Pharma Inc. is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 15.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ALPMY has returned about 10.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 6.8%. This means that Astellas Pharma Inc. is outperforming the sector as a whole this year.
Another stock in the Medical sector, BillionToOne (BLLN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 15.1%.
The consensus estimate for BillionToOne's current year EPS has increased 612.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Astellas Pharma Inc. belongs to the Medical - Drugs industry, a group that includes 133 individual companies and currently sits at #146 in the Zacks Industry Rank. On average, this group has lost an average of 5.4% so far this year, meaning that ALPMY is performing better in terms of year-to-date returns.
On the other hand, BillionToOne belongs to the Medical - Products industry. This 78-stock industry is currently ranked #150. The industry has moved -24.7% year to date.
Investors interested in the Medical sector may want to keep a close eye on Astellas Pharma Inc. and BillionToOne as they attempt to continue their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Astellas Pharma Inc. (ALPMY - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Astellas Pharma Inc. is a member of the Medical sector. This group includes 887 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 15.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ALPMY has returned about 10.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 6.8%. This means that Astellas Pharma Inc. is outperforming the sector as a whole this year.
Another stock in the Medical sector, BillionToOne (BLLN - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 15.1%.
The consensus estimate for BillionToOne's current year EPS has increased 612.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Astellas Pharma Inc. belongs to the Medical - Drugs industry, a group that includes 133 individual companies and currently sits at #146 in the Zacks Industry Rank. On average, this group has lost an average of 5.4% so far this year, meaning that ALPMY is performing better in terms of year-to-date returns.
On the other hand, BillionToOne belongs to the Medical - Products industry. This 78-stock industry is currently ranked #150. The industry has moved -24.7% year to date.
Investors interested in the Medical sector may want to keep a close eye on Astellas Pharma Inc. and BillionToOne as they attempt to continue their solid performance.